Acorda Therapeutics (ACOR) Misses Q4 EPS by 6c, Sales Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- L3Harris CEO steps down amid conduct review, shares drop
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
UPDATE: Goldman Sachs Upgrades Acorda Therapeutics, Inc. (ACOR) to Neutral
February 15, 2017 6:35 AM EST(Updated - February 15, 2017 6:42 AM EST)
Goldman Sachs upgraded Acorda Therapeutics, Inc. (NASDAQ: ACOR) from Conviction Sell to Neutral.
Analyst Salveen Richter comments "Our Sell thesis was based on Ampyra IP challenges resulting in an overhang on ACOR shares, plateauing sales and an... More
